Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for...
Latest articles
[column] Is contentmarketing eigenlijk inbound marketing?
Zit ik een stuk te lezen dat gaat over digitale assets en content assets. ‘Zorg voor één centrale opslag voor alle digitale assets. Dit heeft als belangrijk voordeel dat alle content makkelijk terug te vinden is voor...
New screening test detects 20 types of cancer
Researchers from the Dana-Farber Cancer Institute have developed a new blood test that would accurately determine the presence of several types of cancers. The results of their multi-centre clinical trial to prove the...
Novartis reports positive Phase 3 PALLADIUM results in uncontrolled asthma
Novartis has announced that its investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate) was superior to mometasone furoate (MF) in improving through forced expiratory volume...
Abbott’s COAPT trial data shows MitraClip device is cost effective, increases life expectancy and improves quality of life
Abbott announced new analyses of the landmark COAPT Trial that show the company’s MitraClip device is cost effective and is projected to increase both life─expectancy and quality of life compared to...
EMA committee recommends approval of Bristol─Myers Squibb’s new Opdivo dosing regimen
Bristol─Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) flat dosing schedule of 240 mg...
